Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12724MR)

This product GTTS-WQ12724MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12724MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4742MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ14543MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ10929MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ9082MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ12309MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ3075MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ9601MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ3357MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW